Table 3.

Treatment options and response

Case	Regimens	Treatment options	Response
1	VRD, ECHOP and lenalidomide maintenance therapy	Chemotherapy after surgery	PR
2	BAD and lenalidomide maintenance therapy	Chemotherapy and radiotherapy after surgery	PD soon after CR, then reached PR after undergoing Car-T therapy in another hospital
3	T-CAD, BAD and thalidomide maintenance therapy	Chemotherapy	CR
4	T-CAD and thalidomide maintenance therapy	Chemotherapy after surgery	CR
5	T-CAD, BAD, B-CEVAD and thalidomide maintenance therapy	Chemotherapy and radiotherapy after surgery	CR
6	T-CAD ,BAD and thalidomide maintenance therapy	Chemotherapy	CR
7	CAD,R-DECP, BED and lenalidomide maintenance therapy	Chemotherapy after surgery	CR

VRD: Bortezomib, Lenalidomide and Dexamethsone; BAD regimen (Bortezomib, Doxorubicin and Dexamethsone); CAD: Ifosfamide, Epirubicin or Piraubicin and Dexamethsone; T-CAD: Thalidomide and CAD; B-CEVAD: Bortezomib, Etoposide, ifosfamide, Vindesine sulfate, Epirubicin, and Dexamethsone; BED regimen: (Bortezomib, Etoposide and Dexamethsone; CR: Complete remission; PR: Partial remission; PD: Disease progression.